However, due to the existence of the independent resistance mechanisms, which will give more advantages to the pathological growth of CML cells [36], the detection based on the BCR-ABL1 fusion gene may not be able to accurately evaluate the treatment response and develop more personalized treatment plans. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.